Persistent　human　papillomavirus　(HPV)　infection,　especially　with　high-risk　types　such　as　HPV16　and　HPV18,　has　been　identified　as　the　primary　cause　of　cervical　cancer.　E6　and　E7　are　the　major　onco-proteins　of　high-risk　HPVs,　which　are　consistently　expressed　in　HPV　infected　tissues　but　absent　in　normal　tissues　and　represent　ideal　therapeutic　targets　for　immunotherapy　of　cervical　cancer.In　this　study,　the　optimized　fusion　gene　HPV18　E6E7　(HPV18　ofE6E7)　was　constructed　according　to　genetic　codon　usage　for　human　genes.　At　the　same　time,　for　safety　future　clinical　application,　a　mutant　of　HPV18　ofE6E7　fusion　gene　was　generated　by　site-directed　mutagenesis　at　L52G　for　the　E6　protein　and　C98G　for　the　E7　protein.HPV18-E6E7　mutant　(HPV18　ofmE6E7)　constructed　in　this　work　not　only　lost　the　transformation　capability　for　NIH　3T3　cells　and　tumorigenicity　in　BALB/c　nude　mice,　but　also　maintained　very　good　stability　and　antigenicity.These　results　suggest　that　the　mutant　should　undergo　further　study　for　application　as　a　safe　antigen-　specific　therapeutic　vaccine　for　HPV18-associated　tumors.